Colon Cancer: NSABP C13 (Iowa Cancer Specialists)

NSABP C-13: A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)

Objective

This study is being done to test whether the oral (by mouth) drug, regorafenib, is effective in reducing the risk of colon cancer recurring after patients have received standard chemotherapy (called adjuvant chemotherapy).

The main purpose of this study is to compare the effects (good and bad) of regorafenib to placebo when given to patients with high-risk colorectal cancer after they have completed adjuvant chemotherapy.

Regorafenib is an oral targeted therapy for cancer. A targeted therapy stops cancer cells from growing by targeting and blocking proteins that help cancer cells grow. Regorafenib is approved by the U.S. Food and Drug Administration (FDA) for use in treating colorectal cancer that has metastasized (spread) beyond the colon and nearby lymph nodes to other parts of the body. Regorafenib is considered investigational in this study because it has not been approved by the FDA for use in patients with colon cancer that has not metastasized (early-stage colon cancer).

Placebo, for this study, is a tablet that looks like regorafenib but contains no medication.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Colon
Sponsor(s)
National Surgical Adjuvant Breast and Bowel Project
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Medical Center, West Central Park
    1401 West Central Park
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email